To gain a deeper understanding of the development needs of enterprises, provide precise services for the innovative growth of enterprises, and promote the high-quality development of Qingpu District's biopharmaceutical industry, on March 31, 2025, Li Yujie, Deputy Director of the Qingpu District Economic Commission, led a team, together with relevant personnel from Qingpu Industrial Park, Qingfa Group, Songyuan Fund, and Zhangjiang Yunlifang, to visit and investigate Shanghai Constream Biotechtechnology Co., Ltd. (hereinafter referred to as "Constream Biotech"), conducting an on-site inspection of the company's research and development achievements and operating conditions, and holding discussions on policy support, industrial collaboration, and capital docking.

Picture 1: On-site meeting

In-depth investigation: Focusing on enterprise technological innovation and industrial layout

Dr. Tao Weihong, CEO of Constream Biotech, reported to the leaders on the rapid development of the company since its establishment in 2023. The report focused on the characteristics of Constream Biotech's fully human Fab synthetic phage library and the company's current operating conditions. The investigation team visited Constream Biotech's R&D center and listened to detailed reports on the company's core technologies, team members, and market prospects. As a key biopharmaceutical enterprise in Qingpu District, Constream Biotech focuses on biopharmaceutical R&D services and has already established cooperation with leading innovative pharmaceutical companies in China. Its innovative achievements have obtained multiple domestic patents. Director Li Yujie fully affirmed the company's adherence to independent innovation and its development strategy of cultivating specialized fields, and encouraged the company to accelerate its industrialization process and seize the commanding heights of the industry.

Precise service: Government-enterprise collaboration to solve development challenges

At the meeting, the Qingpu District Economic Commission, the Industrial Park, and Qingfa Group introduced the regional biopharmaceutical industry plan, carrier space support, and supporting policies. They responded on-site to issues raised by the company regarding financing needs, talent introduction, and industrial chain docking. The heads of Songyuan Fund and Zhangjiang Yunlifang proposed a collaborative "fund + base" plan from the perspectives of capital empowerment and science and technology innovation ecology, helping the company accelerate the transformation of scientific and technological achievements. Deputy Director Li Yujie emphasized that Qingpu District will continue to optimize the business environment, integrate resources such as parks, capital, and technology, and provide "full life cycle" services for enterprises. She hopes that Constream Biotech will fully utilize its role as an innovation entity and grow together with the Qingpu biopharmaceutical industrial cluster.

Looking to the future: Jointly building a new ecosystem for industrial development

This visit is a pragmatic measure to deepen Qingpu District's "shopkeeper" service concept, demonstrating the determination of the government and park platforms to work together to serve enterprises. Dr. Tao Weihong, CEO of Constream Biotech, said: "With the support of various departments in Qingpu District, the company will increase R&D investment, expand application scenarios, and contribute to the high-quality development of the regional economy." Next, Qingpu District will continue to conduct enterprise visits around key industrial fields, promote the implementation of policies and resource docking, and create a more competitive industrial ecosystem.

Picture 2: Group photo